Folate-antibody conjugates as lysosomal targeted degradation agents
By developing a bifunctional lysosomal targeted degradation agent containing folic acid and protein binding parts, the problem of lack of selectivity for targeted degradation in the prior art is solved, and efficient degradation of cancer cell membrane proteins and extracellular proteins is achieved, which significantly inhibits the Tumor growth.
Patent Information
- Application Number
- CN202380029377.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-22
- Filing Date
- 2023-03-22
- Publication Date
- 2024-11-22
AI Technical Summary
Existing targeted protein degradation techniques are difficult to selectively degrade extracellular or membrane proteins, especially in cancer cells, and the target delivery lacks selectivity due to the ubiquitous expression of CIM6PR.
A bifunctional lysosome-targeted degrading agent has been developed, containing a folic acid moiety or its analogue to a protein binding moiety, inducing selective targeting and degrading membrane or extracellular proteins through folic acid receptors, such as antibodies labeled with folic acid Binding with EGFR or PD-L1 promotes internalization and degradation of proteins.
Targeted degradation of specific cancer cells is achieved, and the degradation efficiency of membrane proteins or extracellular proteins is enhanced. Especially in cancer cells, it significantly reduces the expression of targets and inhibits tumor growth.
Smart Images

Figure BDA0005054169760000191 
Figure BDA0005054169760000192 
Figure HDA0005054169770000011
Abstract
Description
[0001] Federal Funding Statement
[0002] This invention was made with government support under Grant GM120357 from the National Institutes of Health. The government has certain rights in this invention.
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] Priority is hereby claimed to provisional application 63 / 322,426 filed on March 22, 2022, the contents of which are incorporated herein by reference. Background Art
[0005] Targeted protein degradation (TPD) is emerging as an exciting therapeutic option to combat diseases involving abnormally expressed or mutated pathogenic proteins by engaging our body's natural protein disposal system. Chimeric molecule TPD is a new therapeutic approach (Deshaies, 2020, Nature. 580: 329-338). These chimeras are heterobifunctional molecules that bind to the target (interest) protein (POI) at one end and direct the resulting complex to a certain degradation pathway at the other end. So far, protein degradation targeting chimeras (PROTACs) have received the most attention (see Sakamoto et al., 2001, Proc. Natl. Acad. Sci. 98: 8554-8559; Luh et al., 2020, Angew. Chem. Int. Ed. 59: 15448-15466; Wu et al., 2020, Nat. Struct. Mol. Biol. 27: 605-614). PROTAC contains an E3 ligase ligand that can direct the target protein to the proteasome for degradation (Lai and Crews, 2017, Nat. Rev. Drug Discovery. 16: 101-114; Salami and Crews, 2017, Science. 355: 1163-1167; Cromm and Crews, 2017, Cell Chem. Biol. 24: 1181-1190; Toure and Crews, 2016, Angew. Chem. Int. Ed. 55: 1966-1973). However, PROTAC can only deplete intracellular proteins. There are many disease targets that are membrane proteins or extracellular proteins.
[0006] To expand the scope of targets, researchers have reported a method to label extracellular protein targets with ligands of membrane receptors involved in the active transport of molecules into cells. The labeled proteins are naturally shuttled to lysosomes in cells, where they are degraded. Bifunctional lysosomal targeted degraders are usually produced by conjugating ligands of lysosomal targeting receptors (LTRs) on the cell surface to ligands that can bind to extracellular protein targets. The process is schematically shown in Figure 1 As shown. The LTRs used in previous studies are carbohydrate-binding proteins, including the cation-independent mannose 6-phosphate receptor (CIM6PR or insulin-like growth factor-II receptor) (Banik et al., 2020, Nature. 584: 291-297) and the asialoglycoprotein receptor (ASGPR) (Zhou et al., 2021, ACS Cent. Sci. 7: 499-506; Ahn et al., 2021, Nat. Chem. Biol. 17: 937-946; Caianiello et al., 2021, Nat. Chem. Biol. 17: 947-953). Receptor-ligand interactions trigger the internalization of extracellular proteins through receptor-mediated endocytosis, further inducing the degradation of targets in lysosomes.
[0007] A bifunctional lysosomal targeted degrader was developed by conjugating the ligand of CIM6PR on the cell surface to a molecule that binds to an extracellular protein target (Banik et al., 2020, Nature. 584: 291-297). This bifunctional lysosomal-targeted degrader that attracts the CIM6PR type is also called a lysosomal targeting chimera (LYTAC). CIM6PR is ubiquitously expressed in most cell types. Receptor-ligand interactions trigger the internalization of extracellular proteins through receptor-mediated endocytosis, further inducing the degradation of targets in lysosomes. CIM6PR is a transmembrane receptor that transports proteins with N-glycans capped with mannose 6-phosphate (M6P) residues to lysosomes (Ghosh et al., 2003, Nat. Rev. Mol. Cell Biol. 4: 202-213; Coutinho et al., 2012, Mol. Genet. Metab. 105: 542-550). Early studies have shown that albumin modified with M6P increases cellular uptake (Beljaars et al., 1999, Hepatology. 29: 1486-1493). Subsequently, CIM6PR was used to deliver therapeutic drugs conjugated to M6P derivatives for lysosomal enzyme replacement therapy and cancer treatment (Ghosh et al., 2003, Nat. Rev. Mol. Cell Biol. 4: 202-213; Gary-Bobo et al., 2007, Curr. Med. Chem. 14: 2945-2953). Various molecules, such as peptides, proteins or liposomes, are covalently linked to M6P or its analogs to achieve targeted drug delivery (Hoogendoorn et al., 2014, Angew. Chem. Int. Ed. 53: 10975-10978; Crucianelli et al., 2014, RSC Adv. 4: 58204-58207; Das et al., 2016, Acs Macro Letters. 5: 809-813; Agarwal et al., 2016, Chem. Commun. 52: 327-330; Hyun et al., 2018, Cell Chem. Biol. 25: 1255-1267). In order to expand the use of the CIM6PR / M6P system to targeted protein degradation, LYTACs were constructed by conjugating a mixture of polyglycopeptides containing 20 to 40 units of M6P analogs to antibodies to POI. Unlike the drug delivery process, which involves internalization of a covalently linked M6P-protein target, LYTACs allow transport of a complex formed by non-covalent interactions between the protein target and LYTAC.Studies have shown that LYTAC can successfully degrade secretory and membrane proteins in lysosomes through CIM6PR (Banik et al., 2020, Nature. 584: 291-297). However, the challenges associated with the synthesis and connection of heterogeneous mixtures of polymeric glycopeptides with 20 to 40 units of M6P analogs to antibodies used in the LYTAC system limit its application in drug development. In addition, since CIM6PR is ubiquitously expressed in most cell types, POI is delivered to all cell types non-selectively. There is still an unmet need for selective degradation of extracellular proteins. Summary of the invention
[0008] Provided herein is a bifunctional lysosomal targeted degrader comprising a folate portion or an analog thereof, and a protein binding portion; the folate portion or the analog thereof is configured to bind to a folate receptor as a shuttle molecule for lysosomal degradation; and the protein binding portion is configured to bind to a membrane protein or an extracellular protein.
[0009] In one implementation, the protein binding portion of the bifunctional degrader is configured to bind to a membrane protein. The membrane protein can be a membrane receptor. For example, the membrane receptor can be (as an example and not limitation) an epidermal growth factor receptor (EGFR). The membrane protein can be an immunosuppressive receptor or a ligand of an immunosuppressive receptor, such as CD47. The membrane protein can also be an immune checkpoint molecule. For example, an immune checkpoint molecule can be programmed cell death ligand 1 (PD-L1).
[0010] In another implementation, the protein binding portion of the bifunctional degrader is configured to bind to an extracellular protein. The extracellular protein can be, by way of example and not limitation, a ligand of a membrane receptor, a ligand of an autoantibody, a ligand of a secreted protein, a ligand of a mutant protein, etc.
[0011] The protein binding moiety of the bifunctional degrader can be any type of moiety capable of binding to a membrane protein or an extracellular protein to be targeted for degradation via the endosomal / lysosomal pathway. In some aspects, the protein binding moiety is selected from a polypeptide, a ligand, an aptamer, a nanoparticle, and a small molecule.
[0012] In one implementation, the protein binding portion of the bifunctional degrader is a small molecule.
[0013] In another implementation, the protein binding portion of the bifunctional degrader is a polypeptide.
[0014] The protein binding portion can be an antibody, or a complete antibody or antibody fragment, wherein the fragment retains protein binding activity. The antibody or its fragment is preferably configured to bind to a membrane receptor, a ligand of a membrane receptor, an immunosuppressive receptor, a ligand of an immunosuppressive receptor, an immune checkpoint molecule, an autoantibody, a secretory protein or a mutant protein. In a specific implementation of a bifunctional lysosomal targeted degrader, the antibody is configured to bind to EGFR protein. In one embodiment, the antibody is Cetuximab. In another embodiment, the antibody is configured to bind to CD47 protein. The antibody may also be configured to bind to PD-L1 protein. In one embodiment, the antibody is Atezolizumab.
[0015] The bifunctional degrader may also comprise a linker that links the folate moiety or its analog to the protein binding moiety. Preferred linkers include polyethylene glycol ("PEG"), N-hydroxysuccinimide ("NHS"), and the like, alone or in combination.
[0016] By binding to the folate receptor, the bifunctional lysosomal targeted degraders disclosed herein selectively target cells expressing the folate receptor. This includes cancer cells and other tumor cells expressing the folate receptor.
[0017] Also provided herein is a pharmaceutical composition comprising any bifunctional lysosomal targeted degradation agent disclosed herein. The bifunctional lysosomal targeted degradation agent can be administered alone or in combination with a pharmaceutically acceptable carrier configured for any selected route of administration (e.g., enteral, parenteral, topical, rectal, etc.).
[0018] Also provided herein is a method for degrading a membrane protein or an extracellular protein, comprising contacting the membrane protein or the extracellular protein with any bifunctional lysosome-targeted degrader disclosed herein, wherein the bifunctional lysosome-targeted degrader shuttles the membrane protein or the extracellular protein to a lysosome for degradation.
[0019] Also provided herein is a method comprising administering to an individual in need thereof an amount of any pharmaceutical composition of the present disclosure effective for treating and inhibiting tumor cell growth. In some embodiments, the individual is a human. In some embodiments, the individual suffers from cancer.
[0020] The objects and advantages of the present disclosure will be more fully apparent from the following detailed description of the preferred embodiments of the present disclosure in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 Degradation of a target extracellular protein (POI) induced by a chimeric degrader via a lysosomal targeting receptor (LTR) is shown.
[0022] Figure 2A The chemical structure of FA-PEGn-NHS is shown. Figure 2B The chemical structures of DBCO-PEG3-NHS and N3-PEGn-FA are shown.
[0023] Figure 3 Shown is a series of three graphs indicating the fluorescence intensity of NA-650 uptake by Hela cells (left panel), HepG2 cells (middle panel), and MCF7 cells (right panel) treated with FA-PEG3-biotin ("NA-650+FA-biotin") or without FA-PEG3-biotin ("NA-650").
[0024] Figure 4A Shown are MALDI-MS spectra of anti-mouse IgG Fab fragments labeled with folate ("Fab-FA") or without folate ("Fab").
[0025] Figure 4B Shown are MALDI-MS spectra of full-size anti-mouse IgG labeled with folate ("Ab-FA") or not ("Ab").
[0026] Figure 5A and 5B Shown are gel fluorescence analyses of mouse anti-biotin-IgG-647 protein uptake by Hela cells treated with folate-labeled antibodies ("Ab-FA" and "Fab-FA") or antibodies alone ("Ab" and "Fab"). Figure 5C for Figure 5B Bar graphs of relative fluorescence intensities of the indicated gel bands.
[0027] Figure 6 Shown is a gel fluorescence analysis of mouse anti-biotin-IgG-594 protein uptake by A549 cells, HepG2 cells, FaDu cells, and Hela cells treated with folate-labeled antibody ("Ab-FA") or antibody alone ("Ab").
[0028] Figure 7 MALDI-MS spectra of Ctx, Ctx-FA1, Ctx-FA2, and Ctx-FA3 are shown.
[0029] Figure 8 Western blots of EGFR in Hela cells treated with Ctx, Ctx-FA1 and Ctx-FA2 at 3 nM, 10 nM and 30 nM for 48 hours (upper panel) and 72 hours (lower panel) are shown. Actin was used as a loading control. "-" represents a negative control.
[0030] Fig. 9Western blots of EGFR in Hela cells treated with Ctx and Ctx-FA at 0.1 nM, 1 nM and 10 nM for 6 and 48 hours are shown. Actin was used as a loading control.
[0031] “-” represents negative control.
[0032] Fig.10 Western blots of EGFR in various cancer cell lines treated with Ctx and Ctx-FA ("degrader") at 10 nM for 48 hours are shown. Actin was used as a loading control. "-" represents a negative control.
[0033] Fig.11 Shown are Western blots of EGFR and LTR (folate receptor) in various cell lines treated with Ctx-FA at 10 nM for 48 hours. Actin was used as a loading control.
[0034] Fig.12 Shown according to Fig.11 Gel images of EGFR and LTR normalized to actin.
[0035] Fig.13 Shown according to Fig.12 The percentage of EGFR degradation and the ratio of LTR / EGFR in multiple cell lines were calculated based on the data.
[0036] Fig.14 Shown are Western blots of phosphorylated EGFR (pEGFR) and MAPK (pMAPK) in cells pretreated with 10 nM Ctx-FA ("degrader") for 24 hours and then incubated with 100 ng / ml EGF for 10 minutes or 60 minutes. Actin was used as a loading control.
[0037] “-” represents negative control.
[0038] Fig.15 Western blot of EGFR in HepG2 hepatocytes treated with Ctx, Ctx-oligomeric M6P, Ctx-tri-GalNAc(GN) and Ctx-FA is shown. Actin was used as a loading control.
[0039] Fig.16 Western blots of EGFR, p-EGFR, pAkt, and pMAPK in Cal27 head and neck cancer cells treated with M6P-Ctx and Ctx-FA at 10 nM and 300 nM are shown. Actin was used as a loading control. "-" represents a negative control.
[0040] Fig.17Western blots of EGFR, p-EGFR, pAkt, and pMAPK in FaDu head and neck cancer cells treated with M6P-Ctx and Ctx-FA at 10 nM and 300 nM are shown. Actin was used as a loading control. "-" represents a negative control.
[0041] Fig.18A and 18B The results show that the concentrations of M6P-Ctx and Ctx-FA at 0 nM, 0.1 nM, 1 nM, 10 nM and 100 nM ( Fig.18A ) for 0, 2, 4, 6, 8, 16, 24, 48 and 72 hours ( Fig.18B Western blot of EGFR, pAkt, and pMAPK in Hela cells with 5% paraformaldehyde (P<0.05). Actin was used as a loading control.
[0042] Fig.19 Western blots of EGFR in FaDu cells (upper panel) and HepG2 cells (lower panel) co-treated for 6 hours with 10 nM Ctx-FA ("degrader") and 200 nM bafilomycin ("BAF") or 3 mM folic acid ("ligand") are shown, compared to cells treated with Ctx-FA ("degrader") alone. Actin was used as a loading control. "-" represents a negative control.
[0043] Fig. 20A and 20B Shown are confocal microscopic images of EGFR and a lysosomal membrane marker (LAMP1) in FaDu head and neck cancer cells. Fig. 20A Shown are two views of the same well of FaDu cells treated with 10 nM Ctx-FA for 24 hours. Fig. 20B Shown is a comparison of FaDu cells treated with 10 nM of a Ctx-FA degrader for 24 hours (upper panel) and not treated with a Ctx-FA degrader (lower panel).
[0044] Fig.21 Shown are MALDI-MS spectra of Atz labeled with folate ("Atz-FA") or not ("Atz").
[0045] Fig. 22 Western blots of PD-L1 in various cancer cell lines treated with 10 nM Atz-FA ("Degrader") or Atz alone ("Atz") for 24 hours are shown. Actin was used as a loading control. "-" represents a negative control.
[0046] Fig.23Western blots of CD47 in HepG2 and MDA-MB-231 cells treated with 10 nM of folate-labeled CD47 antibody ("anti-CD47-degrader") or antibody alone ("anti-CD47"). Actin was used as a loading control. "-" represents a negative control. DETAILED DESCRIPTION
[0047] Provided herein are bifunctional lysosomal targeted degraders, comprising: (a) a folate moiety or a folate analog, the folate moiety or folate analog being configured to bind to a folate receptor as a shuttle molecule for lysosomal degradation; and (b) a protein binding moiety (or referred to herein as a "protein binder"), the protein binding moiety being configured to bind to a target membrane protein or an extracellular protein. The bifunctional degraders disclosed herein can be used, for example, to selectively target degradation of membrane proteins and extracellular proteins through an endosomal / lysosomal pathway. In one aspect, the bifunctional degraders induce degradation of oncogenic proteins specific to cancer cells through folate receptors that are overexpressed in many cancer cells. Also provided herein are compositions comprising bifunctional degraders, and methods of using bifunctional degraders to inhibit disease states (including cancer).
[0048] It should be understood that the bifunctional degraders, compositions and methods disclosed herein are not limited to the specific embodiments described, which may, of course, vary. It should also be understood that the terminology used herein is only for the purpose of describing specific embodiments and is not intended to be limiting.
[0049] It should be noted that as used herein and in the appended claims, the singular forms "a, an," and "the" include plural references unless the context clearly dictates otherwise. The term "or" means "and / or." Unless otherwise indicated herein, the recitation of a numerical range is intended merely as a shorthand method of individually referencing each individual value falling within the range, and each individual value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and are independently combinable.
[0050] It should be understood that certain features of the bifunctional degraders, compositions, and methods described in the context of separate embodiments for the sake of clarity may also be combined in a single embodiment. Conversely, various features of the bifunctional degraders, compositions, and methods described in the context of a single embodiment for the sake of brevity may also be provided separately or in any suitable subcombination. All combinations of the embodiments are specifically included in the present disclosure and are disclosed herein, just as each and every combination is individually and explicitly disclosed, as long as these combinations contain operable processes and / or compositions. In addition, all subcombinations listed in the embodiments describing these variables are also specifically included in the bifunctional degraders, compositions, and methods of the present invention and are disclosed herein, just as each and every such subcombination is individually and explicitly disclosed herein. It should also be noted that the bifunctional degraders, compositions, and methods provided herein can be appropriately implemented without any element not specifically disclosed herein.
[0051] Bifunctional lysosomal targeted degraders
[0052] Provided herein is a bifunctional lysosomal targeted degradation agent, comprising folic acid or its analogs, wherein the folic acid or its analogs are configured to bind to a folic acid receptor as a shuttle molecule for lysosomal degradation, and are operably connected to a protein binding portion ("protein binding agent"), wherein the protein binding portion is configured to bind to a target membrane protein or an extracellular protein. As used herein, "operably connected" means that the folic acid portion (or folic acid analog portion) can be directly or indirectly connected to the protein binding agent. Therefore, a direct connection can include a direct chemical bond between the two portions (without any intermediate atoms), or there can be any described connecting portion ("connecting agent") between the folic acid portion (or folic acid analog portion) and the protein binding portion.
[0053] Folic acid is a small molecule that crosses the cell membrane by binding to the folate receptor. As disclosed herein, folic acid is linked to a binding agent of a target membrane protein or an extracellular protein to produce a folate-protein binding degrader. Once inside the cell, folic acid enters the endosome, where the target protein cargo is deposited, and the target protein is then degraded.
[0054] The term "folate analog" as used herein refers to a part that is structurally similar to folic acid and is configured to bind to a folate receptor. The term "folate analog" includes, but is not limited to, folinic acid, pteroglutamic acid, and folate receptor binding pteridines, such as tetrahydropterin, dihydrofolate, tetrahydrofolate, and denitrogenation and didezo analogs thereof. The terms "denitrogenation" and "didenitrogenation" analogs refer to analogs recognized in the art in which one or two nitrogen atoms are replaced by carbon atoms in the natural folic acid structure, or analogs thereof or derivatives thereof. For example, denitrogenation analogs include 1-denitrogenation, 3-denitrogenation, 5-denitrogenation, 8-denitrogenation, and 10-denitrogenation folic acid analogs. Didezo analogs include, for example, 1,5-didenitrogenation, 5,10-didenitrogenation, 8,10-didenitrogenation, and 5,8-didenitrogenation folic acid analogs. Other folic acid analogs that can be used as complex-forming ligands include folic acid receptor binding analogs aminopterin, methotrexate (methotrexate), N10-methylfolate, 2-deaminohydroxyfolate, deaza analogs such as 1-deazamethotrexate or 3-deazamethotrexate and 3', 5'-dichloro-4-amino-4-deoxy-N10-methylpteroylglutamate (dichloromethotrexate). These folic acid analogs are often referred to as "folates," reflecting their ability to bind to the folic acid receptor. Other folic acid analogs that bind to the folic acid receptor are described in U.S. patent applications Nos. 2005 / 0227985 and 2004 / 0242582, which are incorporated herein by reference.
[0055] The folate receptor, or folate binding protein, comprises a single-chain glycoprotein that is able to bind and promote the uptake of folate and other compounds in the body (Elwood, 1989, J. Biol. Chem. 264: 14893-14901). Certain folate receptors are single-chain glycoproteins with high affinity binding sites for folate and other compounds such as methotrexate. The size of the mature folate receptor glycoprotein is approximately 42 kDa and has been observed to be involved in the internalization of folate and antifolates into cells (Elwood et al., 1997, Biochemistry 36: 1467-1478). The folate receptor gene family includes four members: FRα or FOLR1, FRβ or FOLR2, FRγ or FOLR3 and FRδ or FOLR4 (Leamon and Jackman, 2008, Vitam Horm. 79: 203-33).
[0056] Folate receptor alpha (FRα) is a glycosylphosphatidylinositol-linked cell surface glycoprotein that has a high affinity for folic acid. Except for low levels of expression in the kidney and lung, most normal tissues do not express FRα. However, high levels of FRα have been found in epithelial ovarian cancer, endometrial adenocarcinoma, adenocarcinoma subtypes of non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC) (Scaranti et al., 2020, Nat. Rev. 17: 349-359). FRα expression is maintained in metastatic lesions and recurrent cancers in patients with ovarian cancer, and FRα expression is observed after chemotherapy for epithelial ovarian cancer and endometrial cancer. Folate receptor β (FRβ) was originally thought to be present only in the placenta, but has also been detected in bone marrow cells and acute myeloid leukemia (Pan et al., 2002, Blood. 100: 594-602). Due to the limited expression of folate receptors, the bifunctional degraders disclosed herein confer selectivity, enabling cells expressing folate receptors to degrade target membrane proteins and extracellular proteins.
[0057] As disclosed herein, the bifunctional lysosomal targeted degrader comprises a protein binding agent configured to bind to a target membrane protein or an extracellular protein. In some embodiments, the protein binding agent binds to a membrane protein.
[0058] In some embodiments, the membrane protein is a membrane receptor. Target membrane receptors include, but are not limited to, stem cell receptors, immune cell receptors, growth factor receptors, cytokine receptors, hormone receptors, receptor tyrosine kinases, receptors in the epidermal growth factor receptor (EGFR) family (e.g., HER2 (human epidermal growth factor receptor 2), etc., receptors in the fibroblast growth factor receptor (FGFR) family, receptors in the vascular endothelial growth factor receptor (VEGFR) family, receptors in the platelet-derived growth factor receptor (PDGFR) family, receptors in the rearrangement during transfection (RET) receptor family, receptors in the Eph receptor family, receptors in the discoidin domain receptor (DDR) family, and mucins (e.g., MUC1).
[0059] In a specific implementation, the membrane receptor is EGFR, which is known to be frequently mutated or overexpressed in different types of human cancers (Yarden and Pines, 2012, Nat Rev Cancer. 12:553-563; Sigismund et al., 2018, Mol. Oncol. 12:3-20).
[0060] Membrane proteins can be immunoinhibitory receptors. As used herein, "immunoinhibitory receptors" are receptors that negatively regulate immune responses present on immune cells. Examples of inhibitory immune receptors include immunoinhibitory receptors of the Ig superfamily, including but not limited to: CD200R, CD300a (IRp 60; mouse MAIR-I), CD300f (IREM-1), CEACAM1 (CD66a), FcγRIIb, ILT-2 (LIR-1; LILRB1; CD85j), ILT-3 (LIR-5; CD85k; LILRB4), ILT-4 (LIR-2; LILRB2), ILT-5 (LIR-3; LILRB3; mouse PIR-B); LAIR-1, PECAM-1 (CD31), PILR-α (FDF03), SIRL-1 and SIRP-α. Other examples of immunosuppressive receptors include sialic acid binding Ig-like lectin (Siglec) receptors, such as Siglec 7, Siglec9, etc. Other examples of immunosuppressive receptors include C-type lectins, including but not limited to: CLEC4A (DCIR), Ly49Q and MICL. Detailed information on immunosuppressive receptors can be found in, for example, Steevels et al., 2011, Eur. J. Immunol. 4: 575-587.
[0061] The membrane protein may optionally be a ligand for an immunosuppressive receptor, an example of which is CD47, which binds to SIRP-α to prevent phagocytosis and is known to be overexpressed in cancer cells (Eladl et al., 2020, J. Hematol. Oncol. 13:96).
[0062] Membrane proteins can also be immune checkpoint molecules including immune checkpoint proteins and ligands. Non-limiting examples of immune checkpoint molecules include members of the PD-1, PD-L1, CTLA4, TIM3, LAG3, TIGIT, and B7 families. In one embodiment, the membrane protein is PD-L1 (programmed cell death ligand 1), which binds to PD-1 (programmed cell death-1) to inhibit apoptosis, and is known to be overexpressed in cancer cells (Yi et al., 2021, J. Hematol. Oncol. 14: 10).
[0063] As disclosed herein, the bifunctional lysosomal targeted degrader comprises a protein binding agent configured to bind to a target membrane protein or an extracellular protein. In some embodiments, the protein binding agent binds to an extracellular protein.
[0064] The extracellular protein can be a ligand of a membrane receptor. Target membrane receptor ligands include, but are not limited to, growth factors (e.g., epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), etc.), cytokines (e.g., interleukins, interferons, tumor necrosis factor (TNF), transforming growth factor β (TGF-β), including any specific subtypes of these cytokines), hormones, etc.
[0065] Alternatively, the extracellular protein can be an antibody, such as an antibody of a membrane protein or other extracellular protein. The antibody can be an autoantibody. "Autoantibody" refers to an antibody produced by the immune system for one or more individual self proteins. Cancer cells can trigger an immune response, resulting in the production of autoantibodies associated with tumors. Non-limiting examples of autoantibodies include rheumatoid factor (RF), antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), anti-double-stranded DNA (anti-dsDNA), anti-centromere antibodies (ACA), anti-cyclic citrullinated peptide antibodies (anti-CCP), extractable nuclear antigen antibodies (ENA), anti-cardiolipin antibodies, beta-2 glycoprotein 1 antibodies, antiphospholipid antibodies (APA), lupus anticoagulants (LA), anti-tissue transglutaminase (anti-tTG), anti-gliadin antibodies (AGA), intrinsic factor antibodies, parietal cell antibodies, thyroid antibodies, smooth muscle antibodies (SMA), anti-mitochondrial antibodies (AMA), anti-glomerular basement membrane (GBM), acetylcholine receptor (AChR) antibodies, etc.
[0066] The extracellular protein may be a secreted protein, including but not limited to secreted growth factors, extracellular matrix degrading proteases, cell motility factors, and immunomodulatory cytokines or other biologically active molecules.
[0067] The extracellular protein may also be a mutated protein.
[0068] When the protein binder of the bifunctional degrader binds to a membrane protein or an extracellular protein, the membrane protein or the extracellular protein may be present on a cancer cell or produced by a cancer cell. "Cancer cell" refers to a cell that exhibits a tumor cell phenotype, which may be characterized by, for example, abnormal cell growth, abnormal cell proliferation, loss of density-dependent growth inhibition, anchorage-independent growth potential, the ability to promote tumor growth and / or development in an immunocompromised non-human animal model, and / or one or more of any suitable cell transformation indicators. As used herein, "cancer cell" may be used interchangeably with "tumor cell", "malignant cell", "neoplastic cell" or "cancerous cell", and includes cancer cells of solid tumors, semi-solid tumors, hematological malignancies (e.g., leukemia cells, lymphoma cells, myeloma cells, etc.), primary tumors, metastatic tumors, and the like. In some embodiments, the membrane protein present on the cancer cell is a tumor-associated antigen or a tumor-specific antigen.
[0069] The protein binder of the bifunctional degrader can be any type of moiety capable of binding to a membrane protein or an extracellular protein to be targeted for degradation via the endosomal / lysosomal pathway. In some aspects, the protein binder is selected from a polypeptide, a ligand (e.g., a ligand of a membrane receptor, wherein the membrane receptor is targeted for degradation), an aptamer, a nanoparticle, and a small molecule.
[0070] The protein binder can be a small molecule. "Small molecule" refers to a compound with a molecular weight of 1000 atomic mass units (amu) or less. In some embodiments, the small molecule is 750amu or less, 500amu or less, 400amu or less, 300amu or less, or 200amu or less. In one embodiment, the small molecule is biotin.
[0071] The protein binding agent can be a polypeptide, such as an antibody. The terms "antibody" and "immunoglobulin" include antibodies or immunoglobulins of any isotype (e.g., IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgE, IgD, IgA, IgM, etc.); complete antibodies (e.g., antibodies consisting of a tetramer of two dimers consisting of heavy and light chain polypeptides); single-chain antibodies; antibody fragments that retain specific binding to membrane proteins or extracellular proteins (e.g., fragments of complete or single-chain antibodies), including but not limited to Fv, single-chain Fv (scFv), Fab, F(ab')2, Fab', (scFv')2, diabodies, and nanobodies; chimeric antibodies; monoclonal antibodies; fully human antibodies; humanized antibodies (e.g., humanized complete antibodies, humanized antibody fragments, etc.) and fusion proteins comprising the antigen-binding portion of an antibody and a non-antibody protein or fragment thereof. The antibody can be detectably labeled, for example, with an in vivo imaging agent, etc. The antibody can be further conjugated to other moieties, such as polyethylene glycol (PEG), etc. Fusion to an antibody Fc region (or a fragment thereof), conjugation to PEG, etc. can be used, for example, to increase the serum half-life of the antibody after administration to a subject.
[0072] In some embodiments, the antibody is configured to bind to a cancer antigen.
[0073] The antibodies may also be configured to bind to the complete complement or a fragment thereof. In some embodiments, the antibodies bind to one or more immunodominant epitopes within the complete complement or a fragment thereof.
[0074] Alternatively, the antibody may bind to a membrane receptor or a membrane receptor ligand.
[0075] Alternatively, the antibody may bind to an epidermal growth factor (EGF) protein, such as human EGF, or one or more immunodominant epitopes in the EGF protein.
[0076] In some embodiments, the antibody is bound to the EGFR protein. In some embodiments, the antibody is bound to one or more immunodominant epitopes in the EGFR protein. In one embodiment, the antibody comprises the CDR present in cetuximab (Ctx). In another embodiment, the antibody comprises the variable light chain and the variable heavy chain present in cetuximab. In a specific embodiment, the antibody is cetuximab.
[0077] In some embodiments, the antibody binds to an immunoinhibitory receptor. In some embodiments, the antibody binds to one or more immunodominant epitopes within an immunoinhibitory receptor.
[0078] In some embodiments, the antibody binds to a ligand of an immunoinhibitory receptor. In some embodiments, the antibody binds to one or more immunodominant epitopes in a ligand of an immunoinhibitory receptor. In some embodiments, the antibody binds to a CD47 protein. In some embodiments, the antibody binds to one or more immunodominant epitopes within a CD47 protein.
[0079] In some embodiments, the antibody is bound to an immune checkpoint molecule. In some embodiments, the antibody is bound to one or more immunodominant epitopes within an immune checkpoint molecule. In some embodiments, the antibody is bound to a PD-L1 protein. In some embodiments, the antibody is bound to one or more immunodominant epitopes within a PD-L1 protein. In one embodiment, the antibody comprises a CDR present in atezolizumab (Atz). In another embodiment, the antibody comprises a variable light chain and a variable heavy chain present in atezolizumab. In a specific embodiment, the antibody is atezolizumab.
[0080] The bifunctional lysosomal targeted degraders disclosed herein can be in any suitable form. In some embodiments, the bifunctional degraders are conjugates. Therefore, in some embodiments, the bifunctional degraders disclosed herein include folic acid conjugated to a protein binder. In some embodiments, one or more linkers can be used to facilitate the conjugation of folic acid to a protein binder. Non-limiting examples of such linkers include ester linkers (e.g., N-hydroxysuccinimide (NHS) esters, sulfo-NHS esters or PFP esters or thioesters), amide linkers, maleimide or maleimido-based linkers, valine-citrulline linkers, hydrazone linkers, N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB) linkers, succinimidyl-4-(A / -maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linkers, vinylsulfone-based linkers; linkers including polyethylene glycol (PEG), such as but not limited to tetraethylene glycol; linkers including propionic acid; linkers including hexanoic acid, and linkers including any combination thereof. In one embodiment, the linker is PEG. In another embodiment, the linker is PEG and NHS.
[0081] In some aspects, the linker is a chemically unstable linker, such as an acid-cleavable linker, which is stable at neutral pH (blood flow pH 7.3-7.5), but hydrolyzed when internalized into the weakly acidic endosomes (pH 5.0-6.5) and lysosomes (pH 4.5-5.0) of target cells (e.g., cancer cells). Chemically unstable linkers include, but are not limited to, hydrazone linkers, oxime linkers, carbonate linkers, and ester linker agents. According to some embodiments, the linker is an enzyme-unstable linker, such as an enzyme-unstable linker that is stable in the bloodstream but after being internalized into the target cell, is enzymatically cleaved by lysosomal proteases (such as cathepsin or plasmin) in the lysosomes of the target cell (e.g., cancer cells). Enzyme-labile linkers include, but are not limited to, linkers comprising a peptide bond, such as dipeptidyl linkers, such as valine-citrulline linkers, such as maleimidocaproyl-valine-citrulline-p-aminobenzyl (MC-vc-PAB) linkers, valine-alanine-p-aminobenzyloxy (Val-Ala-PAB) linkers, etc. Chemically labile linkers, enzyme-labile linkers, and non-cleavable linkers are known and described in detail, for example, in Ducry and Stump, 2010, Bioconjugate Chem. 21: 5-13.
[0082] Folic acid-protein binding agent conjugates can be formed by covalently linking folic acid to a protein binding agent directly or through one or more linker molecules, through one or more functional groups. The following examples section shows an exemplary method for preparing a folic acid and antibody conjugate.
[0083] In some aspects, the bifunctional degrader enhances the degradation of the membrane protein or extracellular protein compared to the degradation of the membrane protein or extracellular protein in the presence of a protein binder alone. According to some embodiments, the bifunctional degrader enhances the degradation of the membrane protein or extracellular protein compared to the degradation of the membrane protein or extracellular protein in the presence of folic acid or a protein binder alone. "Enhanced degradation" herein means that under the same conditions, the membrane protein or extracellular protein is degraded in the presence of a bifunctional degrader, but not in the presence of a protein binder alone or in the presence of folic acid or a protein binder alone; or under the same conditions, in the presence of a bifunctional degrader, the degradation degree of the membrane protein or extracellular protein is greater than the degradation degree of the membrane protein or extracellular protein in the presence of a protein binder alone or in the presence of folic acid or a protein binder alone. When, under the same conditions, the extent of degradation of a membrane protein or an extracellular protein in the presence of a bifunctional degrader is greater than the extent of degradation of the membrane protein or the extracellular protein in the presence of a protein binder alone or in the presence of folic acid or a protein binder alone, the extent of degradation in the presence of a bifunctional degrader may be 1.2 times or more, 1.4 times or more, 1.6 times or more, 1.8 times or more, 2 times or more, 2.5 times or more, 3 times or more, 3.5 times or more, 4 times or more, 4.5 times or more, 5 times or more, 5.5 times or more, 6 times or more, 6.5 times or more, 7 times or more, 7.5 times or more, 8 times or more, 8.5 times or more, 9 times or more, 9.5 times or more, or 10 times or more.
[0084] Composition
[0085] Disclosed herein are compositions comprising any of the bifunctional lysosomal targeted degraders of the present disclosure.
[0086] The composition may optionally include the bifunctional degradation agent of the present disclosure in a liquid medium. The liquid medium may be an aqueous liquid medium, such as water, a buffer solution, etc. One or more additives, such as salts (e.g., NaCl, MgCl2, KCl, MgSO4), buffers (Tris buffer, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), 2-(N-morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid (MOPS), N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS) etc.), protease inhibitors, glycerol etc. may be present in such a composition.
[0087] Also disclosed herein is a pharmaceutical composition comprising any bifunctional lysosomal targeted degrader disclosed herein and a pharmaceutically acceptable carrier. The pharmaceutical composition generally includes a therapeutically effective amount of a bifunctional degrader. A "therapeutically effective amount" refers to a dose sufficient to produce a desired result, for example, an amount sufficient to produce a beneficial or desired therapeutic (including preventive) result, such as reducing cell proliferation in an individual suffering from a cell proliferative disease (e.g., cancer) associated with a membrane protein or extracellular protein bound by a protein binder of a bifunctional degrader. The effective amount can be applied in one or more administrations.
[0088] The bifunctional degraders disclosed herein can be incorporated into a variety of formulations for therapeutic administration. More specifically, the bifunctional degraders can be formulated into pharmaceutical compositions by combining with appropriate pharmaceutically acceptable excipients or diluents, and can be formulated into formulations in solid, semisolid, liquid or gaseous form, such as tablets, capsules, powders, granules, ointments, solutions, injections, inhalants and aerosols.
[0089] Formulations of the disclosed bifunctional degraders suitable for administration to an individual (eg, suitable for human administration) are generally sterile, and may further contain no detectable pyrogens or other contaminants that would prohibit administration to an individual according to the selected route of administration.
[0090] In pharmaceutical dosage forms, the bifunctional degrader may be administered alone or appropriately in combination or in conjunction with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are not intended to be limiting.
[0091] For oral preparations, the bifunctional degraders can be used alone or in combination with suitable additives to form tablets, powders, granules or capsules. For example, conventional additives such as lactose, mannitol, corn starch or potato starch; binders such as crystalline cellulose, cellulose derivatives, gum arabic, corn starch or gelatin; disintegrants such as corn starch, potato starch or sodium carboxymethyl cellulose; lubricants such as talc or magnesium stearate; and if necessary, diluents, buffers, wetting agents, preservatives and flavoring agents can also be added.
[0092] The bifunctional degrader can be formulated into an injectable preparation by dissolving, suspending or emulsifying it in a water-soluble or water-insoluble solvent, such as vegetable oil or other similar oils, synthetic fatty acid glycerides, higher fatty acid esters or propylene glycol; if necessary, conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives can be added.
[0093] The pharmaceutical composition can be in liquid form, lyophilized form, or liquid form reconstituted from a lyophilized form, wherein the lyophilized preparation is reconstituted with a sterile solution before administration. The standard procedure for reconstituted lyophilized compositions is to add back a volume of purified water (usually equivalent to the volume removed during the lyophilization process); however, solutions containing antimicrobial agents can be used to produce pharmaceutical compositions for parenteral administration.
[0094] The water-soluble formulation of the bifunctional degrader can be prepared in a pH buffer solution, for example, in the pH range of about 4.0 to about 8.0, such as about 4.5 to about 7.5, such as about 5.0 to about 7.0. Examples of pH buffers suitable for use in this range include phosphate-, histidine-, citrate-, succinate-, acetate-buffers and other organic acid buffers. The buffer concentration can be about 1 mM to about 100 mM, or about 5 mM to about 50 mM, depending on, for example, the osmotic pressure required by the buffer and the formulation.
[0095] How to use
[0096] Disclosed herein are methods of using the bifunctional lysosomal targeted degraders of the present disclosure.
[0097] Provided herein is a method for degrading membrane proteins or extracellular proteins. This method includes contacting membrane proteins or extracellular proteins with any bifunctional lysosomal targeted degradation agent of the present invention when the bifunctional lysosomal targeted degradation agent shuttles membrane proteins or extracellular proteins to lysosomes for degradation. This method has uses in a variety of applications. In some aspects, the method is carried out in vitro (e.g., in a test tube, cell culture plate or well, etc.), which can be used in, for example, testing and / or research applications. In other aspects, the method is carried out in vivo (e.g., in an individual using a bifunctional degradation agent), which can be used in, for example, clinical / therapeutic applications.
[0098] Also provided are methods comprising administering a therapeutically effective amount of any bifunctional degrader or any pharmaceutical composition of the present disclosure to an individual in need thereof. According to the methods of the present disclosure, a variety of individuals can be treated. Typically, these subjects are "mammals" or "mammals," where these terms are widely used to describe organisms in the class Mammalia, including Carnivora (e.g., dogs and cats), Rodentia (e.g., mice, guinea pigs, and rats), and Primates (e.g., humans, chimpanzees, and monkeys). In some embodiments, the individual is a human.
[0099] An effective amount of a bifunctional degrader (or a pharmaceutical composition comprising the same) is an amount that, when administered alone (e.g., monotherapy) or in combination with one or more other therapeutic agents (e.g., combination therapy), is effective in reducing disease symptoms (e.g., cancer) in a subject by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more, at one or more doses, as compared to the symptoms when not treated with the bifunctional degrader or pharmaceutical composition.
[0100] The method includes administering a therapeutically effective amount of any bifunctional degrader or any pharmaceutical composition of the present disclosure to an individual suffering from cancer. According to these methods, the protein binder of the bifunctional degrader binds to at least a membrane protein or an extracellular protein that contributes to the individual's cancer, and wherein the targeted degradation of the membrane protein or the extracellular protein by the bifunctional degrader is used to treat the individual's cancer. In some aspects, the protein binder binds to a protein selected from the following: a membrane receptor, a membrane receptor ligand, an immunoinhibitory receptor, a ligand of an immunoinhibitory receptor, an immune checkpoint molecule, an autoantibody, a secreted protein, and a mutant protein.
[0101] For example, the individual to be treated may have a cancer characterized by a solid tumor, a semi-solid tumor, a primary tumor, a metastatic tumor, etc. In some embodiments, the individual has a cancer selected from the group consisting of breast cancer, melanoma, lung cancer, colorectal cancer, prostate cancer, glioma, bladder cancer, endometrial cancer, kidney cancer, leukemia (e.g., acute myeloid leukemia (AML)), liver cancer (e.g., hepatocellular carcinoma (HCC), such as primary or recurrent HCC), non-Hodgkin's lymphoma, pancreatic cancer, thyroid cancer, any combination thereof, and any subtype thereof.
[0102] In any method using the bifunctional degraders of the present disclosure, the bifunctional degraders generally enhance the degradation of membrane proteins or extracellular proteins compared to the degradation of membrane proteins or extracellular proteins in the presence of a protein-binding agent alone. Similarly, according to some embodiments, in any method using the bifunctional degraders of the present disclosure, the bifunctional degraders enhance the degradation of membrane proteins or extracellular proteins compared to the degradation of membrane proteins or extracellular proteins in the presence of folic acid or a protein-binding agent alone.
[0103] "Treat," "treating," or "treatment" refers to at least ameliorating the symptoms associated with a medical condition (e.g., a cell proliferative disorder, e.g., cancer) in an individual, wherein improvement is broadly defined as at least reducing the magnitude of a parameter (e.g., symptom) associated with the medical condition being treated. Thus, treatment also includes situations in which the medical condition, or at least symptoms associated therewith, are completely inhibited (e.g., prevented from occurring) or stopped (e.g., terminated), such that the individual no longer suffers from the medical condition, or at least no longer suffers from the symptoms characterizing the medical condition.
[0104] The bifunctional degradant or pharmaceutical composition can be administered to an individual using any available method and suitable route for drug delivery, including in vivo and in vitro methods, as well as systemic and local routes of administration. Conventional and pharmaceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, subcutaneous, intradermal, topical, intraocular, intravenous, intraarterial, intranasal, oral, and other enteral and parenteral routes of administration. In some embodiments, administration is performed by parenteral administration. If necessary, the routes of administration can be combined or adjusted according to the bifunctional degradant and / or the desired effect. The bifunctional degradant or pharmaceutical composition can be administered in single doses or multiple doses. In some embodiments, the bifunctional degradant or pharmaceutical composition is administered intravenously. In some embodiments, the bifunctional degradant or pharmaceutical composition is administered by injection, for example, for systemic delivery (e.g., intravenous infusion) or delivery to a local site.
[0105] Example
[0106] method
[0107] Labeling of antibodies with FA-PEGn-NHS:
[0108] To label the antibody with folic acid (FA), 100 μL of antibody (at a concentration of 1.8 mg / mL) in PBS was mixed with folic acid-NHS ester at a molar ratio of 1:25. The reaction was incubated overnight at room temperature on a rotator and then filtered five times with 500 μL of PBS using a 10 kDa Amicon centrifugal filter. The chemical structure of FA-PEGn-NHS is shown in Figure 2A .
[0109] Labeling of antibodies with DBCO-PEG3-NHS and N3-PEGn-FA:
[0110] To label the antibody with DBCO, 200 μL of the antibody (at a concentration of 1.8 mg / mL) in PBS was mixed with DBCO-PEG3-NHS ester at a molar ratio of 1:25. The reaction was incubated overnight at room temperature on a rotator and then filtered five times with 500 μL of PBS using a 10 kDa Amicon centrifugal filter. The concentration of the DBCO-labeled antibody was then determined by the BCA assay and mixed with N3-PEG-FA at a molar ratio of 1:25. The reaction was incubated overnight at room temperature on a rotator and then filtered five times with 500 μL of PBS using a 10 kDa Amicon centrifugal filter. The chemical structures of DBCO-PEG3-NHS and N3-PEGn-FA are shown in Figure 2B .
[0111] MALDI-MS
[0112] α-Cyano-4-hydroxycinnamic acid (HCCA) was dissolved in 50% acetonitrile / water to make a 10 mg / mL solution as the matrix solution. The sample was adsorbed on an Omix C4 pipette tip, washed three times with 0.1% TFA, and then eluted with 20 μL of 75% acetonitrile / water. 1 μL of the sample solution and 1 μL of the HCCA solution were spotted on the MALDI target plate, mixed thoroughly, and the spot was then allowed to dry at room temperature. MALDI-MS spectra were acquired on a Bruker UltraFlex MALDI-TOF / TOF mass spectrometer operating in linear positive ion mode. The masses were calculated from the windowed raw data in Sigmaplot 13.0 by fitting a Gaussian curve with a constant baseline as an additional free parameter. The parameter starting values were the default values of the program and were automatically iterated 200 times to obtain the fit. Graphs were made in Origin 2020, where high-frequency noise was removed using a 100-point window FFT filter.
[0113] Mouse IgG uptake experiment:
[0114] Cells were plated at 70% confluence in 24-well plates. Complete growth medium supplemented with 50 nM mouse anti-biotin-IgG-647 and 25 nM FA-labeled goat anti-mouse IgG was added sequentially. Cells were incubated at 37 °C for 24 h and then lysed for in-gel fluorescence analysis. Targeted protein degradation:
[0115] Cells were seeded at 70% confluence in 24-well plates. The next day, cells were treated with 10 nM degradation agent for 24 hours or 48 hours and then collected for western blot analysis. For EGFR degradation, 100 ng / ml EGF was added for 10 minutes or 60 minutes after 24 hours of degradation to stimulate the EGFR signaling pathway.
[0116] Western blotting:
[0117] Cells were lysed on ice for 10 minutes in 1X RIPA lysis buffer containing 25mM Tris (pH 7-8), 150mM NaCl, 0.1% (w / v) sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1% (v / v) Triton X-100, protease inhibitor cocktail (Roche, one tablet per 10mL) and 1mM phenylmethylsulfonyl fluoride. The lysate was then centrifuged at 16000g for 15 minutes at 4°C, the supernatant was collected, and the protein concentration was then measured using the BCA assay. The lysate was adjusted to equal amounts, then mixed with 4x Laemmli loading dye, and heated at 99°C for 5 minutes. After cooling, the sample was loaded onto a 7.5% or 12% SDS-polyacrylamide gel electrophoresis and transferred to a PVDF membrane. The membrane was first blocked with 5% (w / v) skim milk in TBS-T wash buffer (137 mM NaCl, 20 mM Tris, 0.1% (v / v) Tween) and then incubated with the primary antibody overnight at 4°C. After washing 3 times with TBST, the membrane was incubated with the secondary HRP-linked antibody for 1 hour and then washed 3 times with TBST. The membrane was then incubated in Clarity ECL substrate for 3 minutes to 5 minutes and immunoblots were acquired by the ChemiDoc MP imaging system.
[0118] Confocal microscopy:
[0119] FaDu cells were seeded at a density of 20,000 cells / well on 8-well chamber slides in 200 μL complete medium. After adhesion, cells were treated with 10 nM Ctx-FA at 37 ° C for 24 hours. The cells were then washed 3 times with PBS and fixed with 4% paraformaldehyde for 15 minutes, followed by permeabilization with 0.5% Triton-100 for 5 minutes. After blocking with 5% BSA for 1 hour at room temperature, the cells were co-incubated with anti-EGFR antibodies and anti-LAMP1 antibodies or EEA1 antibodies in 1% BSA at 4 ° C overnight. The next day, the cells were washed with PBS and then incubated with anti-mouse-488 or anti-rabbit-594 secondary antibodies at room temperature for 1 hour. The slides were then mounted with slow-fade-antifade mounting medium containing DAPI. Images were acquired at 100x magnification using a Leica SP83xSTED super-resolution microscope with a 10x eyepiece and analyzed by ImageJ.
[0120] Competitive Analysis:
[0121] FaDu or HepG2 cells were seeded in 24-well plates at 70% confluence. The next day, cells were co-treated with 10 nM degraders and 200 nM bafilomycin A1 or 3 mM folic acid for 6 h and then collected for western blot analysis.
[0122] Example 1: Uptake mediated by small molecule degraders and antibody-based degraders
[0123] In this example, we tested a small molecule degrader, folic acid-PEG3-biotin (Nanocs), with the following chemical structure:
[0124]
[0125] The folate-PEG3-biotin degrader contains biotin as a protein binder that binds to avidin and streptavidin with high specificity and affinity. By treating Hela, HepG2, and MCF7 cells with or without the folate-PEG3-biotin degrader, we observed a higher uptake of NA-650 (NeutrAvidin-650, a fluorescently labeled protein that biotin strongly binds) in cells treated with the degrader compared to cells treated with NA-650 alone ( Figure 3 ).
[0126] Next, we tested antibody-based degraders that included an antibody as a protein binder and the antibody was labeled with folate-PEG10-NHS having the following chemical structure:
[0127]
[0128] We labeled anti-mouse IgG antibodies (Ab 150 kDa, Fab 50 kDa) with folate-PEG10-NHS and monitored the uptake of the fluorescent protein target mouse anti-biotin-IgG-647 in HeLa cells treated with or without folate-labeled antibodies. Figure 4A and 4B Shown are the MALDI-MS spectra of anti-mouse IgG Fab fragments and full-size anti-mouse IgG labeled with or without folic acid. FIG. 5A to FIG. 5C Gel fluorescence analysis is shown, indicating that the uptake of protein targets in cells treated with folate-labeled anti-mouse IgG antibody was higher than that in cells treated with antibody alone. The uptake of protein targets in Hela cells treated with folate-labeled full-size anti-mouse IgG was higher than that of anti-mouse IgG Fab monomer ( Figure 5A ).
[0129] In general, uptake mediated by small molecule degraders was modest compared to that of antibody-based degraders. In HeLa cells, consistent uptake was observed after 24 h of treatment with antibody-based degraders ( Figure 5B and Figure 5C ).like Figure 6 As shown, uptake of the anti-biotin IgG-594 protein by the antibody-based degrader was also observed in multiple cell lines.
[0130] Example 2: EGFR degradation
[0131] Cetuximab (Ctx) is an approved antibody drug that blocks the function of epidermal growth factor receptor (EGFR) on the cell surface to treat metastatic colorectal cancer and head and neck cancer. (Ctx is available from ImClone LLC of New York, NY under the registered trademark "ERBITUX" , U.S. NDC codes 66733-948-23 and 66733-958-23). The major side effects of Ctx are related to the blockade of EGFR in normal tissues. Selective degradation of EGFR in cancer cells could provide significant therapeutic benefits.
[0132] In this example, we labeled Ctx with folic acid-PEG10-NHS from two different suppliers (Nanocus and Ruixibiotech) to generate degraders Ctx-FA1 and Ctx-FA2. We also labeled Ctx with folic acid-PEG3-NHS to generate degrader Ctx-FA3. Figure 7 MALDI-MS spectra of Ctx, Ctx-FA1, Ctx-FA2, and Ctx-FA3 are shown.
[0133] Our results show that if Figure 8 As shown, Ctx-FA2 can induce EGFR degradation in Hela cells treated for 48 and 72 hours. Fig. 9 As shown, the results with different concentrations of Ctx-FA degrader were reproducible. Fig.10 As shown, EGFR degradation was also observed in multiple cancer cell lines treated with Ctx-FA degraders.
[0134] Compared with the uptake of avidin targets in the medium, we observed that the degradation of the membrane protein EGFR by the Ctx-FA degrader was more efficient. This is in contrast to our previous study of GalNAc-labeled antibodies, in which the uptake of protein targets in the medium was more efficient than the degradation of EGFR (Zhou et al., 2021, ACS Cent. Sci. 7: 499-506).
[0135] Here, we also investigated the correlation between the degradation efficiency and the ratio of LTR (folate receptor) / EGFR expression levels. Fig.11The expression levels of EGFR and LTR in various cell lines treated with 10 nM Ctx-FA for 48 hours are shown. Fig.11 Gel images of EGFR and LTR expression levels normalized to actin ( Fig.12 The percentage of EGFR degradation and the ratio of LTR / EGFR were calculated ( Fig.13 ), but no obvious correlation was found between the percentage of EGFR degradation and the ratio of LTR / EGFR.
[0136] The effect of Ctx-FA degraders was also tested via EGFR signaling. Cells were pretreated with 10 nM Ctx-FA for 24 h and then incubated with 100 ng / ml EGF for 10 min or 60 min to stimulate the EGFR signaling pathway. Proteins were collected for western blotting of phosphorylated EGFR (pEGFR) and MAPK (pMAPK). The results showed that very little pEGFR (pMAPK) was detected in cells treated with Ctx or Ctx-FA degraders. Fig.14 ), indicating that both Ctx and Ctx-FA effectively blocked EGFR signaling.
[0137] Here, we also compared the degradation efficiency of Ctx-FA degrader with other EGFR degraders. Fig.15 As shown in Figure 2, Ctx-FA degraders showed superior EGFR degradation effects in HepG2 hepatocytes treated with Ctx-FA degraders compared with three LTR degraders, including Ctx alone, Ctx-oligomeric M6P, and Ctx-tri-GalNAc(GN). Ctx-FA degraders also showed superior EGFR degradation effects in Cal27 head and neck cancer cells ( Fig.16 ), Fadu head and neck cancer cells ( Fig.17 ) and HeLa cells ( Fig.18A and 18B ) also showed better EGFR degradation efficiency than M6P-Ctx.
[0138] To investigate the mechanism of action of Ctx-FA degraders, Fadu and HepG2 cells were co-treated with Ctx-FA degraders and the lysosomal inhibitors folic acid and bafilomycin (BAF). Co-treatment effectively reduced the degradation of EGFR ( Fig.19 ), indicating that in the presence of Ctx-FA degraders, EGFR degradation is carried out through the lysosomal degradation pathway. Fig. 20A As shown in the confocal microscopy images in Figure 2, co-localization of EGFR with a lysosomal membrane marker (LAMP1) was observed in Fadu head and neck cancer cells treated with 10 nM of Ctx-FA degrader for 24 h; Fig. 20BAs shown by confocal microscopy imaging in , in the absence of Ctx-FA degrader, EGFR is localized on the cell membrane.
[0139] Example 3: Degradation of other cancer-related targets (PD-L1 and CD47) through cancer-specific LTR
[0140] PD-L1 degraders are based on the first FDA-approved PD-L1 antibody, atezolizumab (Atz). Atezolizumab is a commercially available monoclonal antibody marketed under the trade name “TECENTRIQ”. (Genentech, San Francisco, USA) for sale. Fig.21 The MALDI-MS spectra of Atz labeled with or without folic acid are shown. We studied the degradation of PD-L1 in multiple cancer cell lines treated with or without folic acid labeled Atz degraders. The results showed that in most of the tested cells, the folic acid labeled Atz degrader effectively degraded PD-L1 ( Fig. 22 ).
[0141] We also explored CD47 degraders based on CD47 antibodies labeled with folate. Fig.23 Degradation of CD47 in HepG2 and MDA-MB-231 cells treated with degrading agents is shown.
Claims
1. A bifunctional lysosomal targeted degrader, include: a folate moiety or an analog thereof configured to bind to a folate receptor as a shuttle molecule for lysosomal degradation; Operably connected to A protein binding moiety is configured to bind a membrane protein or an extracellular protein.
2. The bifunctional lysosomal targeted degrader of claim 1, wherein the protein binding portion is configured to bind to a membrane protein.
3. The bifunctional lysosomal targeted degrader of claim 2, wherein the protein binding portion is configured to bind to a membrane receptor.
4. The bifunctional lysosomal targeted degrader of claim 3, wherein the protein binding portion is configured to bind to epidermal growth factor receptor (EGFR).
5. The bifunctional lysosomal targeted degrader of claim 2, wherein the protein binding portion is configured to bind to an immunosuppressive receptor.
6. The bifunctional lysosomal targeted degrader of claim 2, wherein the protein binding portion is configured to bind to a ligand of an immunosuppressive receptor.
7. The bifunctional lysosomal targeted degrader of claim 6, wherein the protein binding portion is configured to bind CD47.
8. The bifunctional lysosomal targeted degrader of claim 2, wherein the protein binding portion is configured to bind to an immune checkpoint molecule.
9. The bifunctional lysosomal targeted degrader of claim 8, wherein the protein binding portion is configured to bind programmed cell death ligand 1 (PD-L1).
10. The bifunctional lysosomal targeted degrader of claim 1, wherein the protein binding portion is configured to bind to an extracellular protein.
11. The bifunctional lysosomal targeted degrader according to claim 1, wherein the protein binding moiety is selected from the group consisting of a polypeptide, a ligand, an aptamer, a nanoparticle and a small molecule.
12. The bifunctional lysosomal targeted degrader according to claim 1, wherein the protein binding moiety is a non-protein small molecule.
13. The bifunctional lysosomal targeted degrader according to claim 1, wherein the protein binding moiety is a polypeptide. The bifunctional lysosomal targeted degrader according to claim 1 , wherein the protein binding moiety is an antibody.
15. The bifunctional lysosomal targeted degrader according to claim 14, wherein the antibody is configured to bind to EGFR protein. The bifunctional lysosomal targeted degrader according to claim 15 , wherein the antibody is cetuximab.
17. The bifunctional lysosomal targeted degrader according to claim 14, wherein the antibody is configured to bind to CD47 protein. The bifunctional lysosomal targeted degrader according to claim 14 , wherein the antibody is configured to bind to PD-L1 protein. The bifunctional lysosomal targeted degrader according to claim 18 , wherein the antibody is atezolizumab.
20. The bifunctional lysosomal targeted degrader according to claim 1, further comprising a linker that connects the folate moiety or an analog thereof to the protein binding moiety. The bifunctional lysosomal targeted degrader according to claim 20 , wherein the linker is PEG.
22. The bifunctional lysosomal targeted degrader according to claim 20, wherein the linker is PEG and NHS.
23. The bifunctional lysosomal targeted degrader according to claim 1, wherein the bifunctional lysosomal targeted degrader is configured to selectively target cells expressing folate receptors.
24. The bifunctional lysosomal targeted degrader according to claim 23, wherein the cell expressing the folate receptor is a cancer cell.
25. A pharmaceutical composition comprising the bifunctional lysosomal targeted degradation agent of claim 1.
26. The pharmaceutical composition according to claim 25, further comprising a pharmaceutically acceptable carrier.
27. A method for degrading membrane proteins or extracellular proteins, include: contacting a membrane protein or an extracellular protein with the bifunctional lysosomal targeted degradation agent of claim 1; The lysosome-targeted degrader shuttles the membrane protein or extracellular protein to the lysosome for degradation.
28. A method comprising administering to an individual in need thereof an effective therapeutic, tumor cell growth inhibiting amount of the pharmaceutical composition of claim 25.
29. The method of claim 28, wherein the individual is a human.
30. The method of claim 28, wherein the individual has cancer.
Citation Information
Patent Citations
Folate mimetics and folate-receptor binding conjugates thereof
US20040242582A1
Folate mimetics and folate-receptor binding conjugates thereof
US20050227985A9
